Key Takeaway: NeOnc Technologies has reported positive topline results from its Phase 2a study of intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma. The study achieved its primary endpoint, demonstrating a six-month progression-free survival rate of 48.9%, significantly exceeding the benchmark of 20%. The company intends to request a Type B meeting with the FDA to discuss potential registration pathways.
Market Sentiment Analysis
POSITIVE FACTORS
Study met its primary endpoint with significant results.
Six-month progression-free survival rate was notably high.
Company plans to engage with the FDA for a registrational path.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~0 mo
High dilution risk
Lead asset
Perillyl alcohol
Phase 1 · Glioblastoma Multiforme
Full Press Release Details
Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall
Frequently Asked Questions
What were the results of the Phase 2a study?
The Phase 2a study achieved a six-month progression-free survival of 48.9%.
What is the significance of the 20% benchmark?
The 20% benchmark is the pre-specified standard of care for comparison.
What is NeOnc Technologies planning next?
The company plans to request a Type B meeting with the FDA.
What type of therapy is NEO100 targeting?
NEO100 is targeting recurrent IDH1-mutant high-grade glioma.